Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent rLukS-PV + rAT
- Development stage
- Unknown
- Lead developer
- Vaxart
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Bivalent rLukS-PV + rAT is a recombinant prophylactic vaccine developed to prevent infections caused by *Staphylococcus aureus*, including methicillin-resistant strains. The vaccine contains two recombinant protein antigens: rLukS-PV (a subunit of Panton-Valentine leukocidin) and rAT (recombinant α-toxoid). These components are designed to stimulate the immune system to produce neutralizing antibodies against both α-toxin and PVL, two major virulence factors of *S. aureus*. Clinical studies have shown that the bivalent formulation induces robust antibody responses with functional neutralizing activity in healthy adults, suggesting potential for prevention of *S. aureus* infections[1][2][3][6]. The vaccine was initially developed by Nabi Biopharmaceuticals.
- Other names
- recombinant LukS-PVrecombinant Panton-Valentine leukocidin subunit SrLukS-PV
02
Targets
Hla (Staphylococcus aureus alpha toxin)LukS-PV (Panton-Valentine leukocidin S component)
Beyond the preview
Go deeper on bivalent rLukS-PV + rAT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent rLukS-PV + rAT.